Literature DB >> 17222197

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.

E M Ocio1, R F J Schop, B Gonzalez, S A Van Wier, J M Hernandez-Rivas, N C Gutierrez, R Garcia-Sanz, M J Moro, C Aguilera, J Hernandez, R Xu, P R Greipp, A Dispenzieri, S M Jalal, M Q Lacy, N Gonzalez-Paz, M A Gertz, J F San Miguel, R Fonseca.   

Abstract

Fluorescence in situ hybridisation (FISH) is an effective technique for the cytogenetic analysis of Waldenström macroglobulinemia (WM), but the potential impact of molecular cytogenetics on disease evolution and as a prognostic marker is still unknown. Deletion of the long arm of chromosome 6 (6q-) is the most frequent cytogenetic abnormality in WM. This study analysed the prevalence of this aberration in 102 WM patients, and correlated it with disease characteristics. The incidence of 6q21 deletion was 7% by conventional cytogenetics and 34% when analysed by FISH (54% when cytoplasmic immunoglobulin M-FISH was used). Patients with deletion of 6q displayed features of adverse prognosis, such as higher levels of beta2-microglobulin and monoclonal paraprotein and a greater tendency to display anaemia and hypoalbuminemia. Interestingly, there was a correlation between the presence of 6q deletion and the International Staging System prognostic index (incidence of 6q- among patients stratified in stages 1, 2 and 3 was 24%, 42% and 67% respectively). Those patients diagnosed with smouldering WM who displayed the abnormality showed a trend to an earlier requirement of treatment. Finally, the survival analysis did not show differences between the two groups of patients, probably due to the short follow up of our series.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222197     DOI: 10.1111/j.1365-2141.2006.06389.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 2.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

3.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

4.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Authors:  Florence Nguyen-Khac; Jerome Lambert; Elise Chapiro; Aurore Grelier; Sarah Mould; Carole Barin; Agnes Daudignon; Nathalie Gachard; Stéphanie Struski; Catherine Henry; Dominique Penther; Hossein Mossafa; Joris Andrieux; Virginie Eclache; Chrystèle Bilhou-Nabera; Isabelle Luquet; Christine Terre; Laurence Baranger; Francine Mugneret; Jean Chiesa; Marie-Joelle Mozziconacci; Evelyne Callet-Bauchu; Lauren Veronese; Hélène Blons; Roger Owen; Julie Lejeune; Sylvie Chevret; Hélène Merle-Beral; Véronique Leblondon
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 5.  Novel treatment options for Waldenström macroglobulinemia.

Authors:  Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

Review 6.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

Review 7.  Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.

Authors:  Natalia Neparidze; Madhav V Dhodapkar
Journal:  Clin Adv Hematol Oncol       Date:  2009-10

8.  Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Authors:  Jorge J Castillo; Ramon Garcia-Sanz; Evdoxia Hatjiharissi; Robert A Kyle; Xavier Leleu; Mary McMaster; Giampaolo Merlini; Monique C Minnema; Enrica Morra; Roger G Owen; Stephanie Poulain; Marvin J Stone; Constantine Tam; Marzia Varettoni; Meletios A Dimopoulos; Steven P Treon; Efstathios Kastritis
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

Review 9.  How to manage Waldenstrom's macroglobulinemia.

Authors:  C Buske; V Leblond
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

Review 10.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.